PGT-A, preimplantation genetic testing for aneuploidies, is a genetic test performed on embryos created through IVF to screen for chromosomal abnormalities. PGT-A, formerly known as preimplantation genetic screening (PGS), is used to screen embryos for extra or missing chromosomes. Embryos with extra or missing chromosomes, referred to as aneuploid, often fail to implant and lead to miscarriage or, if implantation is successful, lead to the birth of a child with a genetic condition. Embryos found to be chromosomally normal are referred to as euploid and are the most likely to lead to a successful pregnancy.
With PGT-A, embryos without any detectable missing or extra chromosomes are selected for transfer. PGT-A may:
- Increase the chances of implantation and pregnancy
- Reduce the risk of miscarriage
- Reduce the number of IVF cycles needed to achieve pregnancy
- Increase the chances of giving birth to a healthy baby
PGT-A is appropriate for the vast majority of IVF patients and is recommended for:
- Women who are over the age of 35
- Women who have experienced one or more pregnancy losses
- Women who have had a pregnancy with chromosomal abnormalities
- Women who have experienced unsuccessful IVF cycles
- Couples who want to balance the genders in their family
- Couples challenged by male infertility factor
IVF
Embryos are produced through an IVF cycle.
Embryo Biopsy
A few cells are carefully extracted from the part of the embryo that later forms the placenta. This sample of cells is then sent to PacGenomics while your embryos stay safely in your IVF clinic.
PGT-A
PacGenomics determines with high accuracy and confidence whether each embryo has a normal number of chromosomes or if an aneuploidy is present.
Embryo Selection and Transfer
After testing data is analyzed, PacGenomics provides a PGT report to your care team.